Monopar Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.48, missing the estimate of USD -0.4346.

EBIT: As of FY2025 Q3, the actual value is USD -4.749 M.

Operating Expenses

• Research and Development (R&D) Expenses: For the three months ended September 30, 2025, R&D expenses were $2,589,749, an increase of $1,605,471 from $984,278 in the same period in 2024. For the nine months ended September 30, 2025, R&D expenses were $5,963,124, an increase of $2,881,758 from $3,081,366 in the same period in 2024.
• General and Administrative (G&A) Expenses: For the three months ended September 30, 2025, G&A expenses were $1,503,326, an increase of $912,702 from $590,624 in the same period in 2024. For the nine months ended September 30, 2025, G&A expenses were $4,586,063, an increase of $2,580,352 from $2,005,711 in the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was - $8,831,219, compared to - $4,405,721 in the same period in 2024.
• Net Cash Used in Investing Activities: For the nine months ended September 30, 2025, net cash used in investing activities was - $1,264,561, compared to $0 in the same period in 2024.
• Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $91,959,082, compared to $3,155,428 in the same period in 2024.

Unique Metrics

• Interest Income: For the three months ended September 30, 2025, interest income was $655,473, an increase of $556,129 from $99,344 in the same period in 2024. For the nine months ended September 30, 2025, interest income was $2,033,087, an increase of $1,778,103 from $254,984 in the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to assemble a regulatory package to support an NDA approval for ALXN1840 in Wilson disease patients and advance the development of MNPR-101 for radiopharmaceutical use as both a therapeutic and diagnostic imaging agent.
• Non-Core Business: The company intends to expand its drug development pipeline through internal research and development, as well as by potentially acquiring or in-licensing additional product candidates.